162 results on '"Nijhof, Inger S."'
Search Results
2. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
3. Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).
4. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
5. Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.
6. Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
7. Improving the identification of frail elderly newly diagnosed multiple myeloma patients
8. Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma
9. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
10. Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
11. The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands
12. P1536: SARS-COV-2 INFECTIONS IN PATIENTS WITH HAEMATOLOGIC MALIGNANCIES: EFFECT OF VACCINATION AND THE DEVELOPMENT OF HYBRID IMMUNITY
13. P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
14. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
15. Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019
16. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
17. Supplementary Figure 3 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
18. Supplemental Data from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
19. Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities
20. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
21. Fourth mRNA COVID-19 Vaccination in Immunocompromised Patients with Hematologic Malignancies
22. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
23. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
24. Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies
25. Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination
26. SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
27. Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial
28. MM-355 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
29. Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)
30. MM-329 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)
31. Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
32. Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients
33. SARS-CoV-2 hyperimmune globulin for severely immunocompromised patients with COVID-19: a randomised, controlled, double-blind, phase 3 trial
34. Efficacy and safety of daratumumab combined with all-transretinoic acid in relapsed/refractory multiple myeloma
35. Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study
36. For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation
37. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study
38. Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19
39. Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies
40. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
41. Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
42. Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
43. Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
44. Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients
45. Diffuse plane normolipaemic xanthomatosis as a manifestation of monoclonal gammopathy
46. Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment
47. Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
48. Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
49. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
50. Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.